Clinical trial
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone…
NCT00417079 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00417079 |
|---|---|
| Title | XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer |
| Official title | A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen |
| Acronym | TROPIC |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neoplasms, Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | cabazitaxel (XRP6258) (RPR116258), mitoxantrone, prednisone |
| Enrollment | 755 |
| Start date | Jan 1, 2007 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Dec 29, 2006 |
| Last update posted | Mar 10, 2011 |
| Countries | Argentina, Belgium, Brazil, Canada, Chile, Czechia, Denmark, Finland, France, Germany, Hungary, India and 14 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: